메뉴 건너뛰기




Volumn 119, Issue 1232, 2006, Pages

Interferon beta, PHARMAC, and political directives: In the best interests of people with multiple sclerosis?

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT;

EID: 33646010031     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (6)

References (16)
  • 2
    • 0027418515 scopus 로고
    • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
    • IFNB Multiple Sclerosis Study Group
    • IFNB Multiple Sclerosis Study Group, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-61.
    • (1993) Neurology , vol.43 , pp. 655-661
  • 3
    • 0037442623 scopus 로고    scopus 로고
    • Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis
    • Sudlow CL, Counsell CE. Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ. 2003;326:388-92.
    • (2003) BMJ , vol.326 , pp. 388-392
    • Sudlow, C.L.1    Counsell, C.E.2
  • 4
    • 0033911466 scopus 로고    scopus 로고
    • Long-term treatment of multiple sclerosis with interferon-beta may be cost effective
    • Kendrick M, Johnson KI. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective. Pharmacoeconomics. 2000;18:45-53.
    • (2000) Pharmacoeconomics , vol.18 , pp. 45-53
    • Kendrick, M.1    Johnson, K.I.2
  • 5
    • 0034017018 scopus 로고    scopus 로고
    • Treatment of multiple sclerosis with interferon beta: An appraisal of cost-effectiveness and quality of life
    • Parkin D, Jacoby A, McNamee P, et al. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry. 2000;68:144-9.
    • (2000) J Neurol Neurosurg Psychiatry , vol.68 , pp. 144-149
    • Parkin, D.1    Jacoby, A.2    McNamee, P.3
  • 6
    • 0037426031 scopus 로고    scopus 로고
    • Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis
    • Chilcott, J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ. 2003;326:522-6.
    • (2003) BMJ , vol.326 , pp. 522-526
    • Chilcott, J.1    McCabe, C.2    Tappenden, P.3
  • 7
    • 33645968874 scopus 로고    scopus 로고
    • Multiple sclerosis - Beta interferon and glatiramer acetate (No. 32)
    • National Institute for Health and Clinical Excellence, London: NICE; Available online. URL: Accessed April 2006
    • National Institute for Health and Clinical Excellence, Multiple sclerosis - beta interferon and glatiramer acetate (No. 32). London: NICE; 2001. Available online. URL: http://www.nice.org.uk/ page.aspx?o=27588 Accessed April 2006.
    • (2001)
  • 8
    • 85049085863 scopus 로고    scopus 로고
    • Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: Evaluating disease modifying treatments in multiple sclerosis
    • Miller DH. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ. 2003;326:526.
    • (2003) BMJ , vol.326 , pp. 526
    • Miller, D.H.1
  • 9
    • 33645966399 scopus 로고    scopus 로고
    • Government to fund beta-interferon
    • News release issued by the Minister of Health, 26 December
    • Government to fund beta-interferon. News release issued by the Minister of Health, 26 December 1999.
    • (1999)
  • 10
    • 33645986352 scopus 로고    scopus 로고
    • MS patients welcome move to fund drugs
    • 27 December
    • MS patients welcome move to fund drugs. New Zealand Herald, 27 December 1999.
    • (1999) New Zealand Herald
  • 11
    • 33645973882 scopus 로고    scopus 로고
    • Pharmaceutical schedule
    • PHARMAC. Available online. URL: Accessed April
    • PHARMAC. Pharmaceutical schedule. Available online. URL: http://www.pharmac.govt.nz/pharmaceutical_schedule_update.asp Accessed April 2006.
    • (2006)
  • 13
    • 25844466246 scopus 로고    scopus 로고
    • Ministry for Disability Issues. Available online. URL: Accessed April 2006
    • Ministry for Disability Issues. NZ Disability Strategy; 2001. Available online. URL: http://www.odi.govt.nz/nzds/ about-the-strategy.html#objectives Accessed April 2006.
    • (2001) NZ Disability Strategy
  • 14
    • 0036726904 scopus 로고    scopus 로고
    • Pharmacologic options for the management of multiple sclerosis symptoms
    • Schapiro RT. Pharmacologic options for the management of multiple sclerosis symptoms. Neurorehabilitation and Neural Repair. 2002;16:223-31.
    • (2002) Neurorehabilitation and Neural Repair , vol.16 , pp. 223-231
    • Schapiro, R.T.1
  • 15
    • 10344226168 scopus 로고    scopus 로고
    • A multimodal approach to managing the symptoms of multiple sclerosis
    • Crayton H,. Heyman RA, Rossman HS. A multimodal approach to managing the symptoms of multiple sclerosis. Neurology. 2004;63:S12-18.
    • (2004) Neurology , vol.63
    • Crayton, H.1    Heyman, R.A.2    Rossman, H.S.3
  • 16
    • 33645960317 scopus 로고    scopus 로고
    • Removal of expenditure cap for beta-interferon
    • [Letter from PHARMAC to MS Society of Auckland]; 7 March
    • Removal of expenditure cap for beta-interferon [Letter from PHARMAC to MS Society of Auckland]; 7 March 2002.
    • (2002)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.